XML 129 R40.htm IDEA: XBRL DOCUMENT v3.19.3

Subsequent events	12 Months Ended
	Jun. 30, 2019
Text block [abstract]
Subsequent events	Note 36. Subsequent events Since the end of the financial year the Company signed an agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, whereby MSK will investigate the potential use of Kazia’s investigational new drug, GDC-0084, in combination with radiotherapy in a phase I clinical trail for cancer that has spread to the brain (brain metastases and leptomeningeal metastases). This research will explore a new use of GDC-0084 and will run concurrently with other ongoing studies in different forms of brain cancer.

X

- Definition

The entire disclosure for events after the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 10
-IssueDate 2018-01-01
-Section Disclosure
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=10&date=2018-03-01&anchor=sect_Disclosure&doctype=Standard
-URIDate 2018-03-16

+ Details

Name:	ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Text block [abstract]

+ References

No definition available.

+ Details

Name:	kzia_TextBlockAbstract
Namespace Prefix:	kzia_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration